Shenyang Xingqi Pharmaceutical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100002DV1
CNY
69.40
13.81 (24.84%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

With a growth in Net Profit of 40.39%, the company declared Very Positive results in Mar 25

  • OPERATING CASH FLOW(Y) Highest at CNY 524.17 MM
  • ROCE(HY) Highest at 25.82%
  • NET SALES(Q) At CNY 528.5 MM has Grown at 52.83%
2

With ROE of 28.64%, it has a very attractive valuation with a 7.09 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 12,920 Million (Large Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.05%

stock-summary
Debt Equity

-0.14

stock-summary
Return on Equity

34.79%

stock-summary
Price to Book

6.96

Revenue and Profits:
Net Sales:
741 Million
(Quarterly Results - Sep 2025)
Net Profit:
264 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
38.72%
0%
38.72%
6 Months
15.68%
0%
15.68%
1 Year
-47.97%
0%
-47.97%
2 Years
4.11%
0%
4.11%
3 Years
24.78%
0%
24.78%
4 Years
16.12%
0%
16.12%
5 Years
41.06%
0%
41.06%

Shenyang Xingqi Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
33.24%
EBIT Growth (5y)
63.33%
EBIT to Interest (avg)
91.89
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.18
Sales to Capital Employed (avg)
0.97
Tax Ratio
15.39%
Dividend Payout Ratio
55.32%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
25.75%
ROE (avg)
17.53%

Valuation key factors

Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
7.09
EV to EBIT
21.25
EV to EBITDA
17.95
EV to Capital Employed
7.80
EV to Sales
5.63
PEG Ratio
2.19
Dividend Yield
2.40%
ROCE (Latest)
36.69%
ROE (Latest)
28.64%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 35.34% vs 30.54% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 117.55% vs 28.33% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "741.00",
          "val2": "547.50",
          "chgp": "35.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "302.10",
          "val2": "160.80",
          "chgp": "87.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "1.80",
          "chgp": "-44.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "264.10",
          "val2": "121.40",
          "chgp": "117.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "407.70%",
          "val2": "245.30%",
          "chgp": "16.24%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 32.08% vs 17.59% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 40.88% vs 13.37% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,923.90",
          "val2": "1,456.60",
          "chgp": "32.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "512.70",
          "val2": "349.40",
          "chgp": "46.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.50",
          "val2": "1.90",
          "chgp": "242.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "338.10",
          "val2": "240.00",
          "chgp": "40.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "211.60%",
          "val2": "177.40%",
          "chgp": "3.42%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoYstock-summary

Sep'25
Sep'24
Change(%)
Net Sales
741.00
547.50
35.34%
Operating Profit (PBDIT) excl Other Income
302.10
160.80
87.87%
Interest
1.00
1.80
-44.44%
Exceptional Items
0.00
0.00
Consolidate Net Profit
264.10
121.40
117.55%
Operating Profit Margin (Excl OI)
407.70%
245.30%
16.24%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2025 is 35.34% vs 30.54% in Sep 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 117.55% vs 28.33% in Sep 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
1,923.90
1,456.60
32.08%
Operating Profit (PBDIT) excl Other Income
512.70
349.40
46.74%
Interest
6.50
1.90
242.11%
Exceptional Items
0.00
0.00
Consolidate Net Profit
338.10
240.00
40.88%
Operating Profit Margin (Excl OI)
211.60%
177.40%
3.42%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 32.08% vs 17.59% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 40.88% vs 13.37% in Dec 2023

stock-summaryCompany CV
About Shenyang Xingqi Pharmaceutical Co., Ltd. stock-summary
stock-summary
Shenyang Xingqi Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available